Aptose Biosciences (APTO) to Release Quarterly Earnings on Tuesday

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) is projected to release its earnings data before the market opens on Tuesday, March 25th. Analysts expect Aptose Biosciences to post earnings of ($1.21) per share for the quarter.

Aptose Biosciences Stock Up 2.7 %

Shares of APTO opened at $3.79 on Tuesday. Aptose Biosciences has a 52-week low of $2.39 and a 52-week high of $51.61. The company has a 50-day simple moving average of $5.06 and a 200-day simple moving average of $7.99. The company has a market capitalization of $8.11 million, a PE ratio of -1.28 and a beta of 1.14.

Analyst Ratings Changes

Several analysts have weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $60.00 target price on shares of Aptose Biosciences in a report on Wednesday, February 12th. StockNews.com began coverage on shares of Aptose Biosciences in a research note on Wednesday, March 5th. They issued a “sell” rating for the company. Finally, Alliance Global Partners raised Aptose Biosciences to a “strong-buy” rating in a research note on Thursday, February 27th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average price target of $130.00.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.